In Ireland, WuXi Biologics has sold a new vaccine plant to Merck & Co. for €500 million ($521 million). The New Jersey company was a natural buyer of the facility as it was the lone client WuXi ...

The facility, with a net book value of about $487 million, is a 15,520-square-meter, three-story vaccine manufacturing plant with 200 employees. The deal is expected to be completed in the first ...

WuXi Biologics (OTCPK:WXIBF ... has agreed to sell the plant to Merck (NYSE:MRK) for around $500M, according to Reuters. In late December, WuXi Apptec (OTCPK:WUXIF) said it had agreed to sell ...

WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...

Wuxi invested €200 million in 2019 to build the plant, which currently employs 200 people, alongside a biologics facilities it continues to operate. MSD says it will add 150 jobs to the Dundalk ...

WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing ...

The WuXi Biologics facility is located in Dundalk, Co Louth, in the IDA Science and Technology Park. WuXi invested €200 million in 2019 to build the plant, which currently employs 200 people ...

SHANGHAI and SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing ...